These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24812269)

  • 1. YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway.
    Zhao Y; Khanal P; Savage P; She YM; Cyr TD; Yang X
    Cancer Res; 2014 Aug; 74(16):4493-503. PubMed ID: 24812269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling.
    Zhao Y; Yang X
    Oncotarget; 2015 Sep; 6(26):21906-17. PubMed ID: 26183396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy.
    Wang Z; Chen X; Zhong MZ; Yang S; Zhou J; Klinkebiel DL; Karpf AR; Chen Y; Dong J
    Cell Signal; 2018 Dec; 52():137-146. PubMed ID: 30223016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Cdk1-LATS-Pin1 as a Novel Signaling Axis in Anti-tubulin Drug Response of Cancer Cells.
    Yeung B; Khanal P; Mehta V; Trinkle-Mulcahy L; Yang X
    Mol Cancer Res; 2018 Jun; 16(6):1035-1045. PubMed ID: 29523761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation.
    Yang S; Zhang L; Liu M; Chong R; Ding SJ; Chen Y; Dong J
    Cancer Res; 2013 Nov; 73(22):6722-33. PubMed ID: 24101154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
    Chang WL; Yu CC; Chen CS; Guh JH
    Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
    Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
    PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer.
    Li W; Cao Y; Xu J; Wang Y; Li W; Wang Q; Hu Z; Hao Y; Hu L; Sun Y; Xu G; Ao G
    J Exp Clin Cancer Res; 2017 Oct; 36(1):144. PubMed ID: 29037225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1.
    Chang LC; Yu YL; Liu CY; Cheng YY; Chou RH; Hsieh MT; Lin HY; Hung HY; Huang LJ; Wu YC; Kuo SC
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1303-15. PubMed ID: 25947085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hippo pathway effector Yap is an ovarian cancer oncogene.
    Hall CA; Wang R; Miao J; Oliva E; Shen X; Wheeler T; Hilsenbeck SG; Orsulic S; Goode S
    Cancer Res; 2010 Nov; 70(21):8517-25. PubMed ID: 20947521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells.
    Khanal P; Yeung B; Zhao Y; Yang X
    Sci Rep; 2019 Apr; 9(1):6394. PubMed ID: 31015482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
    Wong SM; Liu FH; Lee YL; Huang HM
    PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity.
    Zeng Y; Stauffer S; Zhou J; Chen X; Chen Y; Dong J
    J Biol Chem; 2017 Sep; 292(36):15028-15038. PubMed ID: 28739871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3.
    Yang S; Zhang L; Purohit V; Shukla SK; Chen X; Yu F; Fu K; Chen Y; Solheim J; Singh PK; Song W; Dong J
    Oncotarget; 2015 Nov; 6(34):36019-31. PubMed ID: 26440309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma.
    Yoshikawa K; Noguchi K; Nakano Y; Yamamura M; Takaoka K; Hashimoto-Tamaoki T; Kishimoto H
    Int J Oncol; 2015; 46(6):2364-70. PubMed ID: 25846049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YAP/TAZ Signaling and Resistance to Cancer Therapy.
    Nguyen CDK; Yi C
    Trends Cancer; 2019 May; 5(5):283-296. PubMed ID: 31174841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LIMD1 phosphorylation in mitosis is required for mitotic progression and its tumor-suppressing activity.
    Zhou J; Zhang L; Zhou W; Chen Y; Cheng Y; Dong J
    FEBS J; 2019 Mar; 286(5):963-974. PubMed ID: 30600590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.